Navigation Links
MU College of Veterinary Medicine to study efficacy of cancer drug in dogs
Date:10/5/2010

COLUMBIA, Mo. A cancer drug that benefits people may soon benefit man's best friend.

Kim Selting, assistant teaching professor of oncology at the MU College of Veterinary Medicine, is the principal investigator in a study that examines the efficacy of Attaxol in dogs with naturally occurring cancer. Attaxol was developed, and is produced, by CritiTech, a Lawrence, Kan. drug development company.

Kim Selting, assistant teaching professor of oncology at the MU College of Veterinary Medicine.

"Cancer is one of the most common causes of death in dogs," Selting said. "This study is important because most chemotherapy drugs available to people can be used in dogs, except for the highly successful taxanes that can keep cancer from proliferating throughout the body. The Attaxol formulation is built specifically for dogs and could allow taxanes to be used by veterinarians."

MU veterinarians will conduct the clinical part of the study and assess cancer response in the dogs involved in the study. Data from an earlier safety study was used to establish a starting dose, and this second study will consist of an escalation phase to determine the optimal dose, followed by an extended treatment. CritiTech scientists will analyze blood samples to determine plasma levels of the drug during the course of treatment. Enrollment of dogs in the study is set to start in mid October, and it is anticipated that the study will take about two years to complete.

The Scott Endowed Program in Veterinary Oncology at MU is one of the largest veterinary oncology programs in the country and actively initiates and participates in clinical trials, as well as provides routine treatment of animals with cancer, including chemotherapy, cancer surgery and radiation therapy.

"We are excited about our continued collaboration with the University of Missouri College of Veterinary Medicine and the commercial opportunity to use CritiTech's fine-particle drug technology in the veterinary field," said Sam Campbell, CritiTech president and chairman.


'/>"/>

Contact: Steven Adams
AdamsST@missouri.edu
573-882-8353
University of Missouri-Columbia
Source:Eurekalert

Related biology news :

1. American College of Medical Genetics receives $13.5M NIH contract
2. Better beer: College team creating anticancer brew
3. College students find comfort in their pets during hard times
4. Texas College Police Unit Deploys BIO-key(R) Mobile Data System
5. High school students paper published in prestigious college math journal
6. NYU College of Dentistry awarded $1.9 million NIH grant for HIV research
7. Empire State Stem Cell Board awards $12.7 million to Albert Einstein College of Medicine
8. Imperial College London and NTU collaborate to offer joint Ph.D. programs in engineering and science
9. Boston College chemistry professor Udayan Mohanty receives a 2009 Guggenheim Fellowship
10. Genetic secrets of date palm unlocked by researchers at Weill Cornell Medical College in Qatar
11. American College of Medical Genetics affirms importance of newborn screening dried blood spots
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... In a new ... in Denmark detail how a patient who developed lymphedema after being treated for breast ... results could change the paradigm for dealing with this debilitating, frequent side effect of ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology: